GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arovella Therapeutics Ltd (ASX:ALA) » Definitions » Net Policyholder Benefits/Claims

Arovella Therapeutics (ASX:ALA) Net Policyholder Benefits/Claims


View and export this data going back to 2002. Start your Free Trial

What is Arovella Therapeutics Net Policyholder Benefits/Claims?

Net Policyholder Benefits/Claims only applies to insurance companies.


Arovella Therapeutics Business Description

Traded in Other Exchanges
Address
84 Hotham Street, Corporate One, Preston, VIC, AUS, 3072
Arovella Therapeutics Ltd is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. The company's lead iNKT cell product is ALA-101. ALA-101 consists of iNKT cells engineered to produce a Chimeric Antigen Receptor (CAR) targeting CD19 on their surface. This CD19-targeting CAR allows the iNKT cells to find and kill tumour cells that express CD19.